Last updated on February 2020

A Study Evaluating MM-310 in Patients With Solid Tumors


Brief description of study

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

Clinical Study Identifier: NCT03076372

Find a site near you

Start Over

Honor Health

Scottsdale, AZ United States
  Connect »

University California San Francisco

San Francisco, CA United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Duke University

Durham, NC United States
  Connect »